Poster preview
ePoster
STAT3 PHOSPHORYLATION INHIBITORS WITH PYRIMETHAMINE AND PIOGLITAZONE PHARMACOPHORES: AN <EM>IN SILICO</EM> AND <EM>IN VITRO</EM> APPROACH FOR DRUG REPURPOSING
Darko Lovićand 6 co-authors
Institute of Physiology and Biochemistry "Ivan Đaja", Faculty of Biology, University of Belgrade
FENS Forum 2026 (2026)
Barcelona, Spain
Board PS04-08PM-245
Presentation
Date TBA
Board: PS04-08PM-245
Event Information
Poster Board
PS04-08PM-245
Poster
View posterAbstract
The activated phosphorylated form of the signal transducer and activator of transcription 3 (pSTAT3) is upregulated in neurological diseases as well as in numerous cancers and inflammatory conditions. STAT3 activity can be inhibited either directly, by blocking phosphorylation at Tyr705 within the SH2 domain or by preventing DNA binding, or indirectly, by targeting upstream cytokine or growth factor receptors and Janus kinases. In this study, we aimed to identify FDA-approved drugs capable of directly inhibiting STAT3 phosphorylation at Tyr705. Pharmacophores derived from two known STAT3 inhibitors, pyrimethamine and pioglitazone, were used to query the DrugBank database. This approach identified 40 approved compounds, of which 32 shared the pyrimethamine pharmacophore. Molecular docking analyses targeting Tyr705, using phospho-L-tyrosine as a control, revealed 15 compounds with stronger predicted binding affinities than the control. The three top-ranked candidates anticancer drugs imatinib, pazopanib, and nilotinib were further evaluated in HeLa and BV2 cells by Western blot. Pazopanib significantly reduced pSTAT3 levels in both cell lines, whereas nilotinib increased pSTAT3 levels in BV2 cells. Although pyrimethamine exhibited a lower predicted binding affinity than phospho-L-tyrosine, it effectively reduced pSTAT3 levels in HeLa cells and showed a trend toward inhibition in BV2 cells. Collectively, these results indicate that pyrimethamine and other FDA-approved drugs sharing its pharmacophore may be repurposed as inhibitors of STAT3 Tyr705 phosphorylation.
Acknowledgment: This work was supported by PRISMA grant 4242 of the Science Foundation Republic of Serbia.
Acknowledgment: This work was supported by PRISMA grant 4242 of the Science Foundation Republic of Serbia.
Recommended posters
IN SILICO CHARACTERIZATION OF AMINO-PYRAZOLE DERIVATIVES AS MULTI-TARGET LIGANDS TO MODULATE ALZHEIMER’S DISEASE AND RELATED TAUOPATHIES VIA GSK-3BETA, FYN, AND DYRK1A INHIBITION
Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
RATIONAL DEVELOPMENT OF PDE9A-TARGETING COMPOUNDS TO MITIGATE NEUROINFLAMMATION: A COMBINED COMPUTATIONAL AND IN VITRO STUDY
Elisa Landucci, Costanza Mazzantini, Giovanni Ribaudo, Alessandra Gianoncelli
DIMETHYL FUMARATE REPURPOSING AGAINST ALPHA-SYNUCLEIN-INDUCED TOXICITY IN MICE
Michela Salvadè, Maria Mancini, Elisa Zianni, Elena Romito, Maria Italia, Davide Franzone, Elena Florio, Paola Poliseno, Vanessa Aragona, Erica Tagliatti, Michela Matteoli, Monica Di Luca, Antonio Pisani, Simona Lodato, Fabrizio Gardoni
MULTILINE IPSC-BASED DRUG REPURPOSING IDENTIFIES N-ACETYLCYSTEINE AND FELODIPINE AS NEUROPROTECTIVE AGENTS ACROSS DISTINCT GENETIC FORMS OF PARKINSON’S DISEASE
Rita Caridade, Bruna Araújo, Catarina Teixeira, Carla Soares-Guedes, Victoria Lievens, Lorenzo Neri, Hanouf Almutairi, Maja Freudenstein, Alan Barragan Filigrana, Gizem Onal, Camille Goldman, Richard Wade-Martins, Hugo JR Fernandes, Fábio G Teixeira
DYRK1A INHIBITION WITH THE NOVEL THERAPEUTIC, DYR533, IN THE PS19 MOUSE MODEL OF TAUOPATHY ATTENUATES TAU PATHOLOGY, NEUROINFLAMMATION, AND SYNAPTIC FUNCTION
Samantha Bartholomew, Wendy Winslow, Nathaniel Hansen, Melissa Martinez, Ritin Sharma, Christopher Hulme, Travis Dunckley, Patrick Pirotte, Ramon Velazquez
STRUCTURE-BASED VIRTUAL SCREENING, IN VITRO AND IN SILICO ANALYSIS IDENTIFIED NOVEL POTENT M6A DEMETHYLASE FTO INHIBITORS AS PROMISING NEUROTHERAPEUTIC AGENTS
Alba Irisarri Martinez, Aina Bellver-Sanchis, Bhanwar Singh Choudhary, Ana Mallo-Abreu, Luis Labrador, Gemma Casadesus, Belén Pérez, Abhisek Jana, Deb Ranjan Banerjee, Isabel Iriepa, Mercè Pallàs, Diego Muñoz-Torrero, Christian Griñán-Ferré